Profile avatar
michaelalbertmd.bsky.social
Co-Founder, Chief Medical Officer @AccomplisHealth | Obesity & Cardiometabolic Medicine | Clinical Incretinology | Healthcare Futurist
32 posts 314 followers 135 following
Prolific Poster

Not taking prescribed medicine can lead to complications. Skipping recommended vaccines increases your vulnerability to preventable diseases. We often forget that choosing to do nothing doesn’t mean living risk-free—it simply means accepting a different set of risks.

In healthcare, the one who pays makes the rules. To drive real change, you either have to forgo insurance and pay out-of-pocket or pass policies that shift power away from insurance companies. Nothing will change until the payer dynamics change. This is a fact.

I’m working on a special podcast project for the obesity scientific community. Do you have a favorite obesity-related podcast for healthcare and science professionals? Drop your recommendations below—I’d love to check them out.

“On Friday morning, the staffers at a half dozen U.S.-funded medical facilities in Sudan who care for severely malnourished children had a choice to make: Defy President Donald Trump’s order to immediately stop their operations or let…babies and toddlers die.” www.propublica.org/article/trum...

📖 NEW from Me: The Weight of Promises The Weight of Promises is an allegory about hope, manipulation, and the quiet power of seeing through the noise. If you’ve ever felt like your struggles were someone else’s profit, this story is for you. 👉 Read it here: medium.com/@MichaelAlbe...

Your obligatory reminder to be careful with chiropractors: Gym-Goer, 29, Dies After Getting Her Neck Adjusted by Chiropractor: ‘Tragic Case’ people.com/woman-29-die...

FDA Violations Rock the Compound Tirzepatide and Semaglutide World - - Great ongoing coverage by @onthepen.bsky.social. Give him a follow. www.onthepen.com/post/fda-vio...

Big News! The FDA has officially approved Novo Nordisk’s Ozempic to treat chronic kidney disease (CKD) in patients with type 2 diabetes (T2D), expanding its already critical role in managing metabolic health. www.cnbc.com/2025/01/28/n...

He’s making little effort to dispel criticism linking him to far-right, neo-Nazi, and modern eugenics ideologies.

Our new vitamins & supplements are here! 🌟 Crafted for bariatric patients and GLP-1 weight loss journeys, they’re 3rd-party tested and made in a certified GMP facility. Shop now: shop.accomplish.health.

Wow, TikTok was a real one till the very end. #tiktokban #blackout

STEP UP Trial Top-lin eResults Novo Nordisk’s STEP UP trial shows semaglutide 7.2 mg achieved 20.7% weight loss with adherence and 18.7% on average over 72 weeks. 33% of participants lost more than 25% of their weight, outperforming semaglutide 2.4 mg and placebo, with a similar safety profile.

The Definition of Obesity Is Changing And What It Means for You ⤵️ medium.com/@MichaelAlbe...

🚨 BREAKING: Zepbound (#Tirzepatide) becomes the first-ever FDA-approved drug for Obstructive Sleep Apnea (OSA)! 🌟 www.fda.gov/news-events/...

BREAKING: Topline results from REDEFINE-1, a Ph3 trial for CagriSema, highlight the novel GLP-1 RA/Amylin RA combo achieving 22.7% weight loss (when paired with diet & exercise) over 68 weeks. CagriSema demonstrates weight loss efficacy comparable to Tirzepatide. www.novonordisk.com/news-and-med...

🚨BREAKING: FDA says Eli Lilly’s weight loss drug Zepbound is no longer in shortage www.cnbc.com/2024/12/19/f...

USC’s Schaeffer Center critiques the CBO’s obesity drug analysis, projecting $1T in benefits over 10 years and $4T over 30 years from comprehensive treatment. healthpolicy.usc.edu/article/cbo-...

The hyperconsumerization of healthcare has fostered a landscape where superficial medicine often thrives. In this piece, I explore the roots of this problem and propose meaningful pathways forward. medium.com/@MichaelAlbe...

Accomplish and ATA Forge Partnership to Deliver Comprehensive Medical Weight Loss and Mental Health Services for Patients with Obesity I'm very excited about this partnership to enhance the mental healthcare of our patients living with obesity. www.accomplish.health/blog/accompl...

🚨Breaking: Lilly’s Zepbound® (tirzepatide) outperforms Wegovy® (semaglutide) in weight loss trial over 72 weeks SURMOUNT-5 Top-line results: 🔹 Zepbound: 20.2% avg. weight loss (50.3 lbs) Vs. 🔹 Wegovy: 13.7% avg. weight loss (33.1 lbs)

🚨 Big News for Oregon! 🚨 Accomplish Health is now LIVE and accepting patients in the Beaver State! 🌟 Don’t wait to start your journey toward better health and confidence. Sign up here: www.accomplish.health/start

GLP-1 Medications Q&A www.accomplish.health/blog/glp1-me...

When there is substantial evidence that food companies have contributed to the development of obesity—which seems inevitable—could we sue them and force them to subsidize obesity care programs?

Liraglutide Impacts Iron Homeostasis in a Murine Model of Hereditary Hemochromatosis academic.oup.com/endo/article...

2025 Open Enrollment Tips: Ensuring Your Obesity Treatment Insurance Coverage Meets Your Needs www.obesityaction.org/2025-open-en...

The Physiological Cycle of Weight Gain

Progress can sometimes feel slow, but there’s no denying that the narrative around obesity is shifting. More people are paying attention, and the conversation is gaining momentum. While there’s still much work ahead, today, I’m feeling grateful. Wishing you all a joyful Thanksgiving! Gobble gobble.

From interim results of Hall’s group: only minimally processed foods led to fat loss, suggesting that even healthier forms of ultra-processed foods (UPFs) might still be problematic—or at the very least, not conducive to fat loss. What a remarkable finding!

MariTide (maridebart cafraglutide) Phase 2 Top-line Results Over 52 Weeks 🔹HbA1c: -2.2% (paired with -17% total body weight loss in T2D patients) 🔹TBWL: Exceeds 20% (in Obesity with no plateau) No new safety concerns were observed, and GI side effects showed rapid tachyphylaxis.

Hello, good people. I know nothing about this platform, but i hear good things. I am looking forward to a future that is less dependent on Elon Musk.